Kent Imaging Inc. is looking to raise $25 million in a series B financing round to expand the use of its imaging device for measuring wound and tissue oxygenation, and to support the launch of a new product, Pierre Lemire, CEO, told BioWorld. Read More
A study presented at the American Society for Radiation Oncology on Oct. 1 offers promise for the treatment of high-grade gliomas using Elekta AB’s Unity MR-Linac system. Read More
The controversy over conflicts of interest for Jeff Shuren, formerly the director of the U.S. FDA’s device center, reached Capitol Hill and may lead to an executive branch investigation into the matter. Read More
Depending on how long it lasts, the dockworkers strike that hit all 14 ports on the U.S. East Coast and along the Gulf Oct. 1 could literally unload a world of hurt to patients and the biopharma/med-tech industries, as it will impact both U.S. imports and exports of life-saving drugs and technologies. Read More
The E4 variant of the APO gene, the R47H variant of the TREM2 gene, and female sex are three of the strongest risk factors for the development of Alzheimer’s disease (AD). By combining all three of them in a mouse model of tauopathy, researchers at Weill Cornell Medical School have identified microglial inflammation and senescence as processes that occurred more strongly in female mice as tauopathy developed. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allurion, Endotronix, Hyperfine, Real Heart, Synchron, Videra. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3Daughters, Alveo, C2N, Cardio diagnostics, Conformal Medical, Edap, Integer Holdings, Lumicell, Mölnlycke, P.G.F. Industry Solutions, Skincure, Spectra Medical, Stemcardia, Theranica , Ultralife, XL Precision. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Atricure, Elucid, Qnovia, Relu, Surmodics. Read More
